These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 12746563)
21. Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Volante M; Bozzalla-Cassione F; DePompa R; Saggiorato E; Bartolazzi A; Orlandi F; Papotti M Virchows Arch; 2004 Aug; 445(2):183-8. PubMed ID: 15252732 [TBL] [Abstract][Full Text] [Related]
22. Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility. Baloch ZW; Abraham S; Roberts S; LiVolsi VA Hum Pathol; 1999 Oct; 30(10):1166-71. PubMed ID: 10534163 [TBL] [Abstract][Full Text] [Related]
23. Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Papotti M; Rodriguez J; De Pompa R; Bartolazzi A; Rosai J Mod Pathol; 2005 Apr; 18(4):541-6. PubMed ID: 15529186 [TBL] [Abstract][Full Text] [Related]
24. Hyalinizing trabecular tumor and papillary carcinoma of the thyroid. Zhu H; Qi JP; Wang YW; Song YJ; Zhang ZY Chin Med J (Engl); 2010 Oct; 123(20):2832-5. PubMed ID: 21034592 [TBL] [Abstract][Full Text] [Related]
25. Differential diagnostic significance of HBME-1, CK19 and S100 in various thyroid lesions. Palo S; Biligi DS Malays J Pathol; 2017 Apr; 39(1):55-67. PubMed ID: 28413206 [TBL] [Abstract][Full Text] [Related]
26. Galectin-3 expression in papillary microcarcinoma of the thyroid. Cvejic D; Savin S; Petrovic I; Paunovic I; Tatic S; Krgovic K; Havelka M Histopathology; 2005 Aug; 47(2):209-14. PubMed ID: 16045783 [TBL] [Abstract][Full Text] [Related]
27. Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hürthle cell and/or apocrine-like changes. Mai KT; Bokhary R; Yazdi HM; Thomas J; Commons AS Histopathology; 2002 Feb; 40(2):133-42. PubMed ID: 11952857 [TBL] [Abstract][Full Text] [Related]
28. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics. Abouhashem NS; Talaat SM Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214 [TBL] [Abstract][Full Text] [Related]
29. Associations Between Nucleus Size, and Immunohistochemical Galectin-3, Cytokeratine-19 and Hbme-1 Markers in Thyroid Papillary Carcinoma: A Morphometric Analyze. Toy H; Etli O; Celik ZE; Sezgin Alikanoglu A Pathol Oncol Res; 2019 Jan; 25(1):401-408. PubMed ID: 29150742 [TBL] [Abstract][Full Text] [Related]
30. Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature. Dunđerović D; Lipkovski JM; Boričic I; Soldatović I; Božic V; Cvejić D; Tatić S Diagn Pathol; 2015 Oct; 10():196. PubMed ID: 26503236 [TBL] [Abstract][Full Text] [Related]
31. Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: improvement in the sensitivity or specificity? Wu G; Wang J; Zhou Z; Li T; Tang F J Int Med Res; 2013 Aug; 41(4):975-83. PubMed ID: 23857157 [TBL] [Abstract][Full Text] [Related]
32. Differential expression of galectin-3 in papillary projections of malignant and non-malignant hyperplastic thyroid lesions. Cvejić D; Savin S; Petrović I; Paunović I; Tatić S; Havelka M Acta Chir Iugosl; 2003; 50(3):67-70. PubMed ID: 15179758 [TBL] [Abstract][Full Text] [Related]
33. Follicular adenoma with papillary architecture: a lesion mimicking papillary thyroid carcinoma. Mai KT; Landry DC; Thomas J; Burns BF; Commons AS; Yazdi HM; Odell PF Histopathology; 2001 Jul; 39(1):25-32. PubMed ID: 11454041 [TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical study of the expression of S-100 protein, epithelial membrane antigen, cytokeratin and carcinoembryonic antigen in thyroid lesions. Mitselou A; Vougiouklakis TG; Peschos D; Dallas P; Boumba VA; Agnantis NJ Anticancer Res; 2002; 22(3):1777-80. PubMed ID: 12168868 [TBL] [Abstract][Full Text] [Related]
35. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma. Nga ME; Lim GS; Soh CH; Kumarasinghe MP Diagn Cytopathol; 2008 Aug; 36(8):550-6. PubMed ID: 18618720 [TBL] [Abstract][Full Text] [Related]
36. HBME-1 expression in hyalinizing trabecular tumours of the thyroid gland. Lenggenhager D; Maggio EM; Moch H; Rössle M Histopathology; 2013 Jun; 62(7):1092-7. PubMed ID: 23617709 [TBL] [Abstract][Full Text] [Related]
37. Contribution of immunocytochemical stainings for galectin-3, CD44, and HBME1 to fine-needle aspiration cytology diagnosis of papillary thyroid carcinoma. Das DK; Al-Waheeb SK; George SS; Haji BI; Mallik MK Diagn Cytopathol; 2014 Jun; 42(6):498-505. PubMed ID: 24273003 [TBL] [Abstract][Full Text] [Related]
38. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Liu YY; Morreau H; Kievit J; Romijn JA; Carrasco N; Smit JW Eur J Endocrinol; 2008 Mar; 158(3):375-84. PubMed ID: 18299472 [TBL] [Abstract][Full Text] [Related]
39. The value of tumor markers in the diagnosis of papillary thyroid carcinoma alone and in combination. Ma H; Xu S; Yan J; Zhang C; Qin S; Wang X; Li N Pol J Pathol; 2014 Oct; 65(3):202-9. PubMed ID: 25372417 [TBL] [Abstract][Full Text] [Related]
40. [Expression of GADD153 in follicular tumors of thyroid and comparison with CK19, Galectin-3 and HBME-1]. Tang QS; Teng XD; Ding W; Zhou J; Yao HT; Ying LX; Xu LM Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):745-8. PubMed ID: 22336157 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]